This study is testing a new medicine called NST-6179 for adults with a liver problem linked to intestinal failure, called Intestinal Failure-Associated Liver Disease (IFALD). People in the study need to have been receiving nutrition through a vein for at least 6 months because their intestines can't absorb enough nutrients. The study is split into two parts. In the first part, participants will take 800 mg of NST-6179 or a placebo (fake medicine) daily for 4 weeks. In the second part, the dose will be 1200 mg for 12 weeks, but this could change based on safety checks.

This research is a randomized, double-blind, placebo-controlled study. This means participants are randomly assigned to receive either the real medicine or a placebo, and neither they nor the researchers know which one they are getting until the study is over. Participants must have a certain level of stable liver health to join and should not have other liver diseases or severe liver damage.

• Study lasts up to 12 weeks.
• Participants must be 18 or older and meet specific health criteria.
• Potential risks and benefits will be discussed with participants.